supp.fit

Omega-3 Fatty Acids and Docosahexaenoic Acid: study protocols

244 study groups took Omega-3 Fatty Acids together with Docosahexaenoic Acid. These are the doses the studies gave. They are not a recommendation.

Omega-3 Fatty Acids: what the research found →

Dose per serving from research: Omega-3 Fatty Acids

241 study groups in 189 studies say how much Omega-3 Fatty Acids participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 g to 2.5 g, 34% of 241 study groups.

Daily doseStudy groups
50 mg or less
5
50 mg to 100 mg
9
100 mg to 250 mg
30
250 mg to 500 mg
30
500 mg to 1 g
57
1 g to 2.5 g
82
2.5 g to 5 g
27
over 5 g
1

Dose per serving from research: Docosahexaenoic Acid

236 study groups in 188 studies say how much Docosahexaenoic Acid participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 g to 2.5 g, 30% of 236 study groups.

Daily doseStudy groups
100 mg or less
4
100 mg to 250 mg
24
250 mg to 500 mg
67
500 mg to 1 g
64
1 g to 2.5 g
71
over 2.5 g
6

Commonly used together

103 of 244 study groups took Omega-3 Fatty Acids and Docosahexaenoic Acid with something else. Shown: what 3 or more different studies gave. The 10 most common of 14.

What was given together, not what works together.

Taken withStudy groups
Fish Oil
49
EPA
14
Vitamin E
12
Lutein
7
Zeaxanthin
7
eicosapentaenoic acid (EPA)
7
Eicosapentaenoic Acid
5
Vitamin A
4
Vitamin D3
4
Choline
3

244 study groups

Study
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis
2026 · fish-oil group · Adults receiving maintenance hemodialysis
4 g800 mg1278 days610
n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes
2011 · EPA-DHA · Adults aged 60–80 with diabetes and a previous myocardial infarction
400 mg149 mg1217 days262
n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes
2011 · EPA-DHA plus ALA · Adults aged 60–80 with diabetes and a previous myocardial infarction
400 mg—1217 days245
CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study
2015 · DHA group · Adults aged 55–85 with early AMD in the study eye and neovascular AMD in the fellow eye
270 mg840 mg3 years127
Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT)
2002 · omega-3 FA group · Patients undergoing balloon-only percutaneous transluminal coronary angioplasty (PTCA)
3 g2.1 g240 days125
Allergic disease in infants up to 2 years of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and lactation
2011 · ω-3-supplemented group · Pregnant women at risk of having an allergic infant, starting in the 25th gestational week and continuing through breastfeeding
1.6 g1.1 g—54
Fish oil supplementation in pregnancy and lactation may decrease the risk of infant allergy
2009 · omega-3 group · Pregnant and breastfeeding women with an allergy themselves or a husband or previous child with allergies
1.6 g1.1 g—52
Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo
2021 · ω-3-FA · Peri- and postmenopausal women younger than 70 with BMI ≥28 and increased breast-cancer risk
2.2 g1.05 g1 year23
The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial
2025 · n-3 PUFAs group · Patients with late-life depression who were euthymic at enrollment; ages and sex not reported
1.2 g1 g52 weeks19
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
2013 · DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye
650 mg350 mg5 years—
Clinical Efficacy and Biological Regulations of ω-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder
2019 · EPA + DHA group · Adults with major depressive disorder
1.5 g700 mg12 weeks—
Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old
2023 · fish oil + placebo · Women in early pregnancy
220 mg1.9 g——
The effect of prenatal docosahexaenoic acid supplementation on infant outcomes in African American women living in low-income environments: A randomized, controlled trial
2016 · Active supplement (groups B and C; identical doses) · African American pregnant women aged 20–30 living in low-income environments, with sea fish consumption below 2 servings per week
90 mg450 mg—43
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye
650 mg350 mg5 years—
Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old
2023 · fish oil + probiotics · Women in early pregnancy
220 mg1.9 g——
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)
2021 · Omega 3 Polyunsaturated Fatty Acids · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait
113 mg400 mg3 years381
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)
2021 · Combined intervention · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait
113 mg400 mg3 years374
The Influence of Prenatal DHA Supplementation on Individual Domains of Behavioral Functioning in School-Aged Children: Follow-Up of a Randomized Controlled Trial
2021 · DHA-rich fish oil · Pregnant women with singleton pregnancies enrolled before 21 weeks’ gestation; no specific diagnosed condition stated
100 mg800 mg—351
Effect of Omega-3 on HLA-DR Expression by Conjunctival Cells and Tear Cytokine Concentrations in the Dry Eye Assessment and Management Study
2022 · active supplement group (ω3) · Adults with moderate to severe dry eye disease
2 g1 g1 year349
Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye
2015 · O3FA group · Symptomatic computer users using computers more than 3 hours per day for at least 1 year; sex and age not specified; computer vision syndrome-related dry eye
360 mg240 mg90 days220
Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials
2021 · DHA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use
270 mg900 mg26 weeks113
Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials
2021 · EPA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use
900 mg360 mg26 weeks112
Fish oil n-3 polyunsaturated fatty acids selectively affect plasma cytokines and decrease illness in Thai schoolchildren: a randomized, double-blind, placebo-controlled intervention trial
2009 · fish oil · Thai schoolchildren aged 9 to 12 years
200 mg1 g26 weeks94
Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study
2009 · Omega-3/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease
600 mg1.7 g1 year89
Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study
2019 · omega-3 fatty acid supplementation · Community-based patients with mild to moderate Alzheimer's disease, MMSE ≥15; 88 participants received supplementation
600 mg1.7 g26 weeks88
Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development
2013 · fish-oil group · Gambian infants, approximately 3–9 months old, living in rural West Kiang; no specific diagnosed condition required
300 mg200 mg26 weeks87
Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study
2009 · Placebo/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease
600 mg1.7 g26 weeks85
Re-Esterified Triglyceride ω-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction: A Randomized Clinical Trial
2024 · ω-3 group · Korean adults aged 20–75 with dry eye disease and concurrent meibomian gland dysfunction; both sexes
1.68 g560 mg12 weeks66
Effects of Marine n-3 Polyunsaturated Fatty Acids on Heart Rate Variability and Heart Rate in Patients on Chronic Dialysis: A Randomized Controlled Trial
2018 · n-3 PUFA group · Adults over 18 years receiving chronic dialysis for more than 3 months
2 g1 g90 days56
Long-chain Polyunsaturated Fatty Acid Supplementation Improves Mood in Elderly Japanese Men
2017 · LCPUFA group · Japanese men aged 55–64 years
100 mg300 mg4 weeks51
The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial
2017 · n-3 PUFA · Chinese adults aged 60 years or older with mild cognitive impairment
720 mg480 mg26 weeks44
Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial
2013 · Fish + S · Adults aged 18–60 years with overweight or obesity (BMI 25–37 kg/m²), otherwise healthy
420 mg210 mg1 year40
Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial
2008 · fish oil group · Pregnant women receiving supplementation from 20 weeks’ gestation until delivery; their children were assessed at age 2.5 years
1.1 g2.2 g—33
Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome
2014 · ω-3 PUFAs arm · Girls aged 12.7 ± 9.1 years on average with typical Rett syndrome and a demonstrated MeCP2 mutation
242 mg/kg71.9 mg/kg1 year33
The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
2024 · n-3 PUFAs group · Adults aged 18–65 with major depressive disorder and HRSD-21 score >18
3.2 g1.1 g12 weeks30
Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial
2021 · DHA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week
270 mg900 mg26 weeks29
Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial
2018 · fish-oil-derived omega-3 fatty acid supplements · heavy-smoker males who smoked at least 20 cigarettes per day
900 mg600 mg90 days27
Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial
2021 · EPA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week
900 mg360 mg26 weeks27
Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial
2022 · FO group · Youth aged 9–21 years with major depressive disorder or Depressive Disorder NOS and a biological parent with bipolar I disorder
2.13 g780 mg12 weeks27
Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment
2018 · FO + BB · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment
1.6 g800 mg24 weeks26
Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial
2021 · Risperidone + fish oil (FO) · Patients aged 15–40 with recent-onset psychosis, including schizophrenia-spectrum and bipolar disorder with psychosis
740 mg400 mg16 weeks25
Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial
2007 · n-3 EFA group · Patients presenting after recurrent self-harm
1.2 g900 mg12 weeks22
Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment
2018 · FO · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment
1.6 g800 mg24 weeks21
Emotion-Related Network Reorganization Following Fish Oil Supplementation in Depressed Bipolar Offspring: An fMRI Graph-Based Connectome Analysis
2021 · Fish oil · Patients aged 9–21 with a depressive disorder and a biological parent with bipolar I disorder
1.47 g780 mg12 weeks21
Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents
1996 · First group: fish oil followed by placebo · Adolescent girls with dysmenorrhea
1.08 g720 mg60 days21
Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents
1996 · Second group: placebo followed by fish oil · Adolescent girls with dysmenorrhea
1.08 g720 mg60 days21
Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure
2006 · omega-3 fatty acid · Adults aged 65 years or older with grade II or III chronic heart failure
1.8 g1.2 g6 weeks20
Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder
2012 · citalopram + omega-3 treatment group · Adults aged 18–65 with major depressive disorder and HAM-D score greater than 17
1 g200 mg8 weeks20
Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects
1990 · low-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified
27 mg/kg18 mg/kg24 weeks20
Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial
2023 · n-3 PUFAs group · Adults with cardiovascular diseases comorbid with major depressive disorder; mean age 60 ± 9 years, 58% male
2 g1 g12 weeks20
Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial
2012 · DHA-rich supplement · Adults older than 65 years with mild cognitive impairment
400 mg1.55 g26 weeks18
The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial
2017 · Fish oil group (FG) · Women aged 18–70 with newly diagnosed, treatment-naïve breast cancer before surgery
940 mg780 mg30 days18
Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial
2012 · EPA-rich supplement · Adults older than 65 years with mild cognitive impairment
1.67 g160 mg26 weeks17
Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects
1990 · high-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified
54 mg/kg36 mg/kg24 weeks17
Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment
2016 · Fish oil group · Older adults with subjective memory impairment, without mild cognitive impairment or dementia; age range and sex distribution not specified
1.6 g800 mg24 weeks15
Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial
2022 · Intervention group · Adults aged 30–70 with stage II–IV, grade B periodontitis
300 mg120 mg90 days15
Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers
2008 · PUFA group · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders
250 mg500 mg90 days13
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
2023 · EPA 1 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL)
1 g1.22 g12 weeks13
Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise
2008 · DHA + EPA · Healthy adult men and women; ages not reported
3 g2 g6 weeks12
Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial
2016 · EPA group · Healthy Japanese men, mean age 19.4 years; no stated diagnosed condition
600 mg260 mg62 days12
Resting metabolic rate and skeletal muscle SERCA and Na(+) /K(+) ATPase activities are not affected by fish oil supplementation in healthy older adults
2020 · Fish oil group · Healthy physically active men and women aged 60–75 years
2 g1 g12 weeks12
4-week eicosapentaenoic acid-rich fish oil supplementation partially protects muscular damage following eccentric contractions
2021 · EPA and DHA group · Healthy recreationally untrained men; age range not stated
3 g260 mg33 days11
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
2023 · EPA 2 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL)
2 g1.22 g12 weeks11
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
2023 · EPA 4 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL)
4 g1.22 g12 weeks11
Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions
2017 · EPA group · Healthy men, mean age 20.7 years; untrained and without a stated diagnosed condition
600 mg260 mg62 days10
The effect of fish oil supplementation on resistance training-induced adaptations
2023 · Fish Oil (FOS) · Adults aged 18–40, men and women, recreationally resistance-trained, without stated chronic disease
2.28 g1.58 g10 weeks10
Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study
2017 · ω-3 EFA supplements · Adults with moderate dry eye disease; age and sex not reported
1 g500 mg90 days8
Supplementation of eicosapentaenoic acid-rich fish oil attenuates muscle stiffness after eccentric contractions of human elbow flexors
2019 · EPA group · Healthy men, approximately 20–22 years old, without resistance training
600 mg260 mg62 days8
Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers
2008 · PUFA group, six-month follow-up subset · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders
250 mg500 mg90 days6
Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis
1992 · Group 2 · Patients with active rheumatoid arthritis
3.8 g2 g16 weeks—
Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis
1992 · Group 3 · Patients with active rheumatoid arthritis
3.8 g2 g16 weeks—
Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study
2007 · omega-3 fatty acids · Children aged 5 to 17 years with autistic disorders accompanied by severe tantrums, aggression, or self-injurious behavior
1.5 g700 mg6 weeks—
Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial
2006 · omega-3 fatty acid-treated group · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified
600 mg1.7 g26 weeks—
Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial
2006 · placebo group after crossover to omega-3 fatty acid supplementation · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified
600 mg1.7 g26 weeks—
Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers
2008 · PUFA group · Men admitted to substance-abuse outpatient clinics, with polysubstance abuse and suboptimal dietary intake of long-chain n-3 PUFAs
2.5 g500 mg90 days—
Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age
2011 · fish-oil group · healthy pregnant women
150 mg500 mg——
Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age
2011 · combined fish-oil and 5-MTHF group · healthy pregnant women
150 mg500 mg——
Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study
2012 · n-3 group · Patients with advanced inoperable non-small-cell lung cancer undergoing chemotherapy
510 mg340 mg66 days—
Fish oil supplementation improves neutrophil function during cancer chemotherapy
2012 · FO · Cancer patients receiving chemotherapy after surgical tumor removal, mainly gastrointestinal cancers; age and sex not stated
300 mg400 mg8 weeks—
The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial
2014 · omega-3 group · Maintenance hemodialysis patients; age range and sex not reported
540 mg360 mg120 days—
Effects of omega-3 fatty acids on tobacco craving in cigarette smokers: A double-blind, randomized, placebo-controlled pilot study
2014 · omega-3 fatty acid supplementation · Regular cigarette smokers
2.71 g2.04 g30 days—
Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder
2015 · ADHD Active · Boys aged 8–14 with ADHD
650 mg650 mg16 weeks—
Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder
2015 · RG Active · Typically developing boys matched to the ADHD participants for age, hand preference, and BMI
650 mg650 mg16 weeks—
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study
2016 · EPA-enriched mix · Adults aged 18–80 with major depressive disorder
1.06 g260 mg8 weeks—
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study
2016 · DHA-enriched mix · Adults aged 18–80 with major depressive disorder
180 mg900 mg8 weeks—
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
2015 · DHA/EPA · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes
650 mg350 mg5 years—
Change in blood levels of eicosapentaenoic acid and posttraumatic stress symptom: A secondary analysis of data from a placebo-controlled trial of omega3 supplements
2016 · omega3 supplements arm · Participants with severe physical injury; age and sex not reported
147 mg1.47 g12 weeks—
ω-3 and ω-6 Fatty Acid Supplementation May Reduce Autism Symptoms Based on Parent Report in Preterm Toddlers
2018 · Omega-3-6-9 Junior treatment · Children aged 18–38 months born at 29 weeks’ gestation or earlier, exhibiting early signs of ASD
338 mg225 mg90 days—
Adding omega-3 fatty acids to a protein-based supplement during pre-season training results in reduced muscle soreness and the better maintenance of explosive power in professional Rugby Union players
2018 · FO · Professional Rugby Union players undergoing pre-season training; age and sex not stated
3.09 g1.1 g5 weeks—
Re-esterified DHA improves ventilatory threshold 2 in competitive amateur cyclists
2020 · DHA · Male amateur cyclists older than 18 years, competing at regional level and training 2–4 sessions per week
1.22 g975 mg30 days—
Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women
2021 · omega-3 group (n-3) · Women aged 55–70 who were overweight or obese and postmenopausal
1.95 g1.65 g16 weeks—
Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women
2021 · omega-3 + resistance training group (n-3+RT) · Women aged 55–70 who were overweight or obese and postmenopausal
1.95 g1.65 g16 weeks—
Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study
1993 · Maxepa · Patients with stable mild rheumatoid arthritis requiring NSAID therapy only; age and sex not reported
1.71 g1.14 g1 year—
The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial
2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition
1 g400 mg18 weeks134
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
100 mg300 mg12 weeks96
Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
2016 · n-3 PUFA treatment · Men and women aged 45–80 with stable coronary artery disease participating in cardiac rehabilitation, with or without a depressive episode
1.9 g600 mg12 weeks46
Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids
2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis
1.42 g480 mg12 weeks40
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
100 mg300 mg24 weeks40
Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children
2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis
600 mg400 mg120 days26
Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment - a randomized clinical trial
2023 · Test group (SRP plus fish oil) · Adults aged 22–70 with generalized stage III or IV periodontitis
2.6 g1.8 g26 weeks24
The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment
2020 · omega supplementation group · Adults aged 65 years or older with mild cognitive impairment
810 mg4.14 g26 weeks23
Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study
2011 · EPA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions
590 mg137 mg30 days22
Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study
2011 · DHA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions
159 mg417 mg30 days22
Benefits of Krill Oil Supplementation During Alternate-Day Fasting in Adults With Overweight and Obesity: A Randomized Trial
2025 · KO group · Healthy adults aged 25–65 with BMI >25 kg/m² and overweight or obesity; 25 women and 16 men enrolled
570 mg188 mg12 weeks21
Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial
2020 · Test group · Adults aged 22–70 with generalized stage III or IV periodontitis
2.6 g1.8 g90 days20
Neuroaspis PLP10™, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson's disease: A randomized, double-blind, placebo-controlled trial
2021 · Neuroaspis PLP10™ · Patients with Parkinson's disease; age and sex not reported.
810 mg4.14 g913 days20
Antioxidant and Anti-Inflammatory Effects of Oral Supplementation with a Highly-Concentrated Docosahexaenoic Acid (DHA) Triglyceride in Patients with Keratoconus: A Randomized Controlled Preliminary Study
2023 · DHA group · Adults aged 18 years or older with stage I–III keratoconus
602 mg500 mg90 days19
21 days of mammalian omega-3 fatty acid supplementation improves aspects of neuromuscular function and performance in male athletes compared to olive oil placebo
2015 · N-3 PUFA · Healthy male athletes competing in summer Olympic sports; ages not otherwise specified
10 g1.02 g3 weeks18
An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot) [ISRCTN22569553]
2004 · Active (fish oil) · University staff aged 18–60 with moderate to high perceived stress
120 mg504 mg6 weeks16
A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study
2016 · Efalex Active 50+ intervention · Women aged 60 years and older, community-dwelling and able to walk at least 50 m and negotiate stairs independently; nonacutely ill
160 mg1 g24 weeks15
Eicosapentaenoic Acid and Medium-Chain Triacylglycerol Structured Lipid Supplementation Improves Muscular Endurance Exercise Performance and Reduces Muscle Fatigue in Young Healthy Male
2025 · EPA/MCT group · Healthy young men
600 mg260 mg8 weeks10
Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients
1999 · fish oil group (T) · Patients with hypercholesterolemia, including hyperlipoproteinemia type IIa and IIb; age and sex not reported
216 mg140 mg6 weeks—
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes
650 mg350 mg5 years—
Omega-3 and -6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: A randomized controlled trial
2017 · treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation and showing significant ASD symptoms
706 mg225 mg90 days—
EPA and DHA as markers of nutraceutical treatment response in major depressive disorder
2020 · combination nutraceutical · Adults with major depressive disorder; age and sex not reported
1 g656 mg8 weeks—
Effects of a Long Chain n-3 Polyunsaturated Fatty Acid-rich Multi-ingredient Nutrition Supplement on Body Composition and Physical Function in Older Adults with Low Skeletal Muscle Mass
2022 · supplement (SUPP) · Community-dwelling older adults with low skeletal muscle mass; mean age 74.9 years; 18 men and 19 women in the study overall
3 g1.5 g26 weeks—
Effects of Omega-3-6-9 fatty acid supplementation on behavior and sleep in preterm toddlers with autism symptomatology: Secondary analysis of a randomized clinical trial
2022 · omega 3-6-9 treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation, with symptoms commonly associated with autism spectrum disorder
1.04 g225 mg90 days—
Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation
2025 · omega-3 group (n-3) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²)
1.95 g1.65 g16 weeks—
Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation
2025 · omega-3 + resistance training group (n-3+RT) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²)
1.95 g1.65 g16 weeks—
Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study
2018 · FO concentrate · Obese men and women with BMI >30
1.6 g1.2 g12 weeks12
Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects
2007 · PS-FO · Men and postmenopausal women aged 30–65 years with mildly overweight hypercholesterolemia
1.7 g3.7 g4 weeks21
Omega-3 fatty acids supplements for dry eye - Are they effective or ineffective?
2023 · O3FA group · Symptomatic visual display terminal users with dry eye; mean age 26.5 years; men and women
360 mg240 mg180 days470
Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN)
2018 · MF4637 omega-3 concentrate · Adults aged 18 years or older with suspected non-alcoholic fatty liver disease (NAFLD)
1.38 g1.14 g24 weeks87
Supplementation of EPA and DHA in pregnant women with type 1 diabetes mellitus
2021 · intervention group · Pregnant women aged 17–35 with type 1 diabetes mellitus and well-controlled glycaemia; supplementation began at 11–12 gestational weeks
120 mg616 mg—42
Habitual diets rich in dark-green vegetables are associated with an increased response to ω-3 fatty acid supplementation in Americans of African ancestry
2014 · EPA + DHA supplementation · Participants of African ancestry; age and sex not stated
2 g1 g6 weeks41
Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index
2010 · n-3 fatty acid drink · Adults with atherosclerotic disease and an n-3 index below 5%
200 mg300 mg8 weeks40
Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults
2025 · microalgal oil arm · Adults aged 21–82, men and women, with fasting triglycerides of 149–450 mg/dL
656 mg1.77 g14 weeks37
Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans
2014 · 2 continuous portions (2C) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition
429 mg506 mg1 year35
Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans
2014 · 2 intermittent portions (2I) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition
429 mg506 mg1 year30
Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial
2022 · Soup · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese
13.6 mg400 mg1 day27
Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial
2022 · Extruded rice snack · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese
13.8 mg400 mg1 day27
Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial
2022 · Gel capsule (control) · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese
14.7 mg400 mg1 day27
Influence of Fish Consumption and ω-3 Supplementation on the ω-3 Index of Young Adults: A 2 × 2 Factorial Randomized Controlled Trial (YouFish Study)
2025 · ω-3 supplement · Healthy young adults aged 18–30 years, male and female, low habitual fish consumers with ω-3 index <6%
400 mg300 mg8 weeks20
Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption
2016 · Calanus Oil condition · Healthy adults; age and sex not specified
4 g156 mg1 day18
Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk
2018 · 675+270 mg/day group · Pregnant women
270 mg——11
Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk
2018 · 225+90 mg/day group · Pregnant women
90 mg——9
Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk
2018 · 450+180 mg/day group · Pregnant women
180 mg——9
In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA
2021 · Lys-FFA · Eight female volunteers
500 mg302 mg1 day8
In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA
2021 · EE · Eight female volunteers
504 mg378 mg1 day8
Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk
2018 · 900+360 mg/day group · Pregnant women
360 mg——7
Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids
2006 · fish oil · 20 study participants; age, sex, and health condition not specified
1.3 g864 mg8 weeks—
Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial
2007 · FO · Pregnant women from gestation week 22 until delivery
150 mg500 mg——
Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial
2007 · FO with MTHF · Pregnant women from gestation week 22 until delivery
150 mg500 mg——
Erythrocyte and plasma fatty acid profiles in patients with epilepsy: does carbamazepine affect omega-3 fatty acid concentrations?
2008 · omega-3 FA supplementation · Patients with epilepsy; age and sex not reported
1 g700 mg12 weeks—
Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats
2015 · Butter meal · Healthy adult men and women
300 mg1.5 g1 day—
Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats
2015 · Sunflower seed oil meal · Healthy adult men and women
300 mg1.5 g1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · unmodified fish oil TAG (uTAG) · Healthy men in the postprandial crossover study
1.1 g370 mg1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · re-esterified TAG · Healthy men in the postprandial crossover study
1.1 g370 mg1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · free fatty acids (FFA) · Healthy men in the postprandial crossover study
1.1 g370 mg1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · ethyl esters (EE) · Healthy men in the postprandial crossover study
1.1 g370 mg1 day—
Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions
2016 · MAG-enriched oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion
500 mg300 mg3 weeks—
Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions
2016 · TAG fish oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion
500 mg300 mg3 weeks—
Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies
2017 · Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder
1.67 g200 mg12 weeks—
Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies
2017 · PEP plus Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder
1.67 g200 mg12 weeks—
Maternal Pre-Pregnancy Obesity Attenuates Response to Omega-3 Fatty Acids Supplementation During Pregnancy
2018 · n-3 PUFA supplementation group · Pregnant women with a history of at least one prior singleton preterm delivery, enrolled at 16 to 21 6/7 weeks; lean, overweight, and obese women were included
1.2 g800 mg8 weeks—
Plasma oxylipins and unesterified precursor fatty acids are altered by DHA supplementation in pregnancy: Can they help predict risk of preterm birth?
2020 · DHA supplementation group · Pregnant Australian women enrolled before 20 weeks of gestation; age and condition range not specified
100 mg800 mg——
Intake of Docosahexaenoic Acid-Enriched Milk Beverage Prevents Age-Related Cognitive Decline and Decreases Serum Bone Resorption Marker Levels
2021 · docosahexaenoic acid-enriched milk beverage · Healthy elderly Japanese individuals with a Mini-Mental State Examination score of 28 or higher at baseline
137 mg297 mg1 year—
Effects of EPA+DHA and Corn Oil Supplementation on PUFA Concentrations across Plasma Lipid Pools and on Downstream Oxylipins: Exploratory Results from a Randomized Controlled Trial in Healthy Humans
2026 · EPA+DHA concentrate · Healthy adults aged 35–49 years; 20 women and 1 man in the available-sample analysis
1.1 g800 mg12 weeks—
Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men
1993 · ethyl ester (EE) · healthy normolipaemic men
2.2 g1.2 g7 weeks—
Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men
1993 · triglyceride (TG) · healthy normolipaemic men
2.2 g1.4 g7 weeks—
Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
1997 · fish diet group · Healthy men aged 19–32 years
380 mg670 mg14 weeks—
Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
1997 · fish oil group · Healthy men aged 19–32 years
1.33 g950 mg14 weeks—
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes
1.86 g1.5 g1 year147
Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial
2017 · Omega-3 ethyl-ester group · Adults aged 21–80 with stable coronary artery disease and overweight or metabolic risk features; predominantly men
3.36 g1.5 g913 days143
Effects of EPA, γ-linolenic acid or coenzyme Q10 on serum prostate-specific antigen levels: a randomised, double-blind trial
2013 · group 1 (n-3 fatty acids) · Healthy men with serum PSA ≤ 2.5 ng/ml
4.48 g2.88 g12 weeks126
Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study
2013 · n - 3/n - 3 group · Older adults with Alzheimer's disease; mean age 75 years; 57% women
600 mg1.7 g1 year89
Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B₄ and leukotriene B₅ production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial
2014 · n-3 FA (active) · Adults aged 41–89 with colorectal cancer awaiting surgery
2 g1 g7 days74
Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes
2016 · omega-3 group · Adults over 18 years with diagnosed dry eye disease, meibomian gland dysfunction stage 1 or 2, and elevated tear osmolarity
1.68 g560 mg12 weeks54
Joint effects of one year of marine omega-3 fatty acid supplementation and participant dietary fish intake upon circulating lipid mediators of inflammation resolution in a randomized controlled trial
2024 · n-3 fatty acid supplementation · Women aged 55 years or older and men aged 50 years or older; participants selected from the VITAL trial by baseline fish intake, without a stated diagnosis
1 g380 mg1 year50
Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study
2020 · EPA+DHA group · Adults with acute coronary syndrome after successful PCI; age and sex mix not restricted
930 mg750 mg1 year48
Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids
2013 · n-3 PUFA / fish oil treatment · Adults with type 2 diabetes and hypertension, and adults with hypertension without diabetes; age- and sex-matched groups
460 mg380 mg8 weeks45
A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha
2002 · 300 mg DHA + 70 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported
70 mg300 mg4 weeks40
A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha
2002 · 600 mg DHA + 140 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported
140 mg600 mg4 weeks40
Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements
2017 · fish oil group · Adults aged 50 and older with symptomatic lower-extremity peripheral arterial disease and intermittent claudication
4.4 g1.8 g30 days40
Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines
2018 · EPA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history
1.06 g274 mg14 weeks37
Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes
2017 · n-3 PUFAs · Adults, mean age 65.6 years, men and women, with type 2 diabetes and established atherosclerotic cardiovascular disease
1 g1 g90 days36
Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines
2018 · DHA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history
180 mg900 mg14 weeks36
Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia
1999 · n-3 fatty acids · Adults with combined (type IIb) hyperlipidaemia who had not responded to a therapeutic diet
4 g4 g12 weeks28
Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers
2014 · Lovaza 1/day · Healthy men and non-pregnant, non-lactating women aged 18–45 years
465 mg375 mg7 weeks28
Body weight affects ω-3 polyunsaturated fatty acid (PUFA) accumulation in youth following supplementation in post-hoc analyses of a randomized controlled trial
2017 · ω-3 supplement group · Children and adolescents aged 7–14 years with mood disorders, including bipolar disorder, major depressive disorder, or dysthymic disorder
2.4 g200 mg12 weeks28
Marine ω-3 PUFA Supplementation Enhances FFAR4 Activation and Reduces Inflammatory Markers in PBMC of Subjects with Obesity: A Randomized Controlled Trial (EPICO)
2025 · marine-derived ω-3 · Adults aged 25–59 years with obesity or abdominal obesity, without major health complications
1.8 g720 mg8 weeks26
Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress--a prospective preliminary study
2002 · group 2 (Maxigard group) · Adults with type 2 diabetes and BMI <27 kg/m²; age and sex not specified
1.2 g240 mg6 weeks25
Generation and dietary modulation of anti-inflammatory electrophilic omega-3 fatty acid derivatives
2014 · fish oil group (treatment) · Healthy adults aged 30–54 years, employed at least 25 hours per week, with dietary EPA and DHA consumption below 300 mg/day
1 g400 mg120 days24
Omega-3 Fatty Acid Could Increase One of Myokines in Male Patients with Coronary Artery Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
2017 · Omega-3 · Men with coronary artery disease and more than 50% stenosis in at least one major coronary vessel
720 mg480 mg8 weeks24
Cytokine distribution in mothers and breastfed children after omega-3 LCPUFAs supplementation during the last trimester of pregnancy and the lactation period: A randomized, controlled trial
2017 · FO group · Pregnant women recruited at week 28 of pregnancy and followed through lactation
72 mg320 mg—24
Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism
2020 · omega-3 FA group · Men aged 35–55 years with fasting plasma TAG concentrations of at least 1.5 mmol/L; nondiabetic and free from known disease
1.84 g1.52 g8 weeks24
Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome
2011 · fish oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m²
2.15 g1.45 g6 weeks21
Secondary data analysis investigating effects of marine omega-3 fatty acids on circulating levels of leptin and adiponectin in older adults
2021 · EPA+DHA Group · Adults aged 50–85 with chronic inflammatory conditions, including nonhealing venous leg ulcers; overweight or obese older adults
1.5 g1 g8 weeks21
N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial
2022 · n-3 FA · Caucasian men and women aged 50–79 with combined hyperlipidemia, taking stable atorvastatin
3 g1 g8 weeks20
Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study
2023 · high-dose EPA/DHA group · Adults aged 20 years or older receiving hemodialysis and diagnosed with dyslipidemia
1.86 g1.5 g90 days19
The effect of highly purified eicosapentaenoic and docosahexaenoic acids on monocyte phagocytosis in man
1997 · highly purified DHA · healthy men
3.6 g3.6 g7 weeks19
Dietary supplementation with fish oil in ulcerative colitis
1992 · fish oil · Adults with active ulcerative colitis
3.24 g2.16 g120 days18
Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach
2014 · FO group · Healthy men and women aged 18–50 years
700 mg900 mg7 weeks17
Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans
2015 · n-3 (EPA+DHA) · Overweight insulin-resistant, nondiabetic adults; 8 men and 23 women were randomized, ages not stated
1.5 g600 mg26 weeks16
Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study
2023 · low-dose EPA/DHA group · Adults receiving hemodialysis and diagnosed with dyslipidemia who continued after the initial control period
930 mg750 mg90 days16
Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F(2)-isoprostanes
2000 · Fish oil · Postmenopausal women
2 g1.4 g—15
Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate
2001 · fish oil (FO) · Postmenopausal women; ages and health conditions not specified
2 g1.4 g—15
Omega-3 fatty acids effect on wound healing
2008 · EPA/DHA supplement group · Healthy men and women aged 18–45 years
1.6 g1.1 g5 weeks15
Dietary supplementation with low-dose omega-3 fatty acids reduces salivary tumor necrosis factor-α levels in patients with chronic periodontitis: a randomized controlled clinical study
2017 · test group · Systemically healthy patients with chronic periodontitis; age and sex not reported
6.25 mg19.2 mg26 weeks15
Supplementation of Re-Esterified Docosahexaenoic and Eicosapentaenoic Acids Reduce Inflammatory and Muscle Damage Markers after Exercise in Endurance Athletes: A Randomized, Controlled Crossover Trial
2020 · DHA + EPA · Healthy male amateur endurance athletes aged 18–45 years
240 mg2.1 g10 weeks15
An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia
2004 · Omacor · 14 patients with familial combined hyperlipidemia (FCHL); age range and sex not reported
1.88 g1.48 g8 weeks14
Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study
2009 · EPA/DHA · Exercise-trained men; ages 25.5 ± 4.8 years; no stated cardiovascular or metabolic disorders
2.22 g2.21 g6 weeks14
Effects of dietary n-3 polyunsaturated fatty acids from plant and marine origin on platelet aggregation in healthy elderly subjects
1999 · EPA/DHA diet, elderly subjects · Adults older than 60 years, healthy elderly subjects
1.05 g550 mg6 weeks13
Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial
2020 · n-3 PUFA group · Adults aged 19 years or older, both sexes, with ultrasound-confirmed non-alcoholic fatty liver disease
306 mg1.51 mg26 weeks13
Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study
2014 · EPA group · Adults older than 65 years with mild cognitive impairment
1.67 g160 mg26 weeks12
Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study
2014 · DHA group · Adults older than 65 years with mild cognitive impairment
400 mg1.55 g26 weeks12
Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study
2018 · High DHA-FO concentrate · Obese men and women with BMI >30
400 mg2 g12 weeks12
Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial)
2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication
4.4 g1.8 g90 days11
Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial)
2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication
4.4 g1.8 g90 days11
The influence of low intake of n-3 fatty acids on platelets in elderly people
1999 · n-3 PUFA group · healthy elderly people; age range and sex not stated
600 mg150 mg6 weeks10
Fish oil supplementation alters levels of lipid mediators of inflammation in microenvironment of acute human wounds
2011 · Active Group (EPA + DHA supplement) · Healthy adults aged 18–45 years, both sexes
1.6 g1.2 g4 weeks9
[Effect of short-term use of omega-3-type polyunsaturated fatty acids in subjects with hypertriglyceridemia]
1992 · fish oil · Patients with hypertriglyceridemia; age and sex not reported
1.8 g1.2 g12 weeks8
Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation
2018 · EPA and DHA (3.4 g/day) · Healthy men aged 29–32 years
1.84 g1.52 g8 weeks3
Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation
2018 · 1800 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group
1.1 g700 mg150 days2
Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation
2018 · 900 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group
550 mg350 mg150 days1
Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics
1999 · FO group · Adults with colonic carcinoma awaiting surgery; ages and sex distribution as reported in the abstract
1.4 g1 g12 days—
Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions
2000 · fish oil (FO) · Healthy subjects; age and sex not specified
2.1 g1.1 g12 weeks—
Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins
2006 · 500 mg DHA + 150 mg eicosapentaenoic acid · Healthy pregnant women during the second half of gestation
150 mg500 mg——
Influence of a concentrated ethylester compound of n-3 fatty acids on lipids, platelets and coagulation in patients undergoing coronary bypass surgery
1991 · n-3 fatty acids · Patients eligible for coronary bypass surgery with fasting triglyceride levels of at least 1.6 mmol/L
3.15 g1.89 g26 weeks—
Effect of n-3 oral supplements on the n-6/n-3 ratio in young adults
2010 · experimental group · healthy young adults
1.6 g1.2 g4 weeks—
Th1 and Th2 chemokines, vaccine-induced immunity, and allergic disease in infants after maternal ω-3 fatty acid supplementation during pregnancy and lactation
2011 · ω-3 fatty acid supplementation · Pregnant women at risk of having an allergic infant
1.6 g1.1 g——
Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients
2012 · treatment group · Adults aged 45–85 years with type 2 diabetes mellitus for at least two years
1.89 g828 mg8 weeks—
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load
2012 · n-3 PUFAs · Patients with combined dyslipidemia; age and sex not specified
3 g1.35 g26 weeks—
Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial
2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified
30 mg100 mg1 year—
Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder
2012 · n-3 group · Children aged 6–12 years with ADHD receiving maintenance therapy
635 mg195 mg8 weeks—
Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study
2015 · n-3 FA treatment · Patients with Alzheimer's disease
600 mg1.7 g26 weeks—
The Pattern of Fatty Acids Displaced by EPA and DHA Following 12 Months Supplementation Varies between Blood Cell and Plasma Fractions
2015 · 1 portion per week · Healthy non-oily-fish-consuming adults; age range and sex distribution not stated
214 mg253 mg1 year—
The effect of 12-wk ω-3 fatty acid supplementation on in vivo thalamus glutathione concentration in patients "at risk" for major depression
2015 · ω-3 FA supplements · Older adults at risk for depression; age range and sex not specified
4 g800 mg12 weeks—
A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease
2017 · krill oil · People with mild to moderate dry eye disease; age and sex not reported
945 mg510 mg90 days—
A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease
2017 · fish oil · People with mild to moderate dry eye disease; age and sex not reported
1 g500 mg90 days—
Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial
2022 · Fish oil · Adults aged 18–65 years, healthy normal-weight participants and participants living with obesity without diagnosed metabolic complications
1.1 g800 mg12 weeks—
The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial
2024 · EPA+DHA supplementation · Adults with coronary artery disease on statin therapy, with and without diabetes
1.86 g1.5 g913 days—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 DHA plus EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye
650 mg350 mg5 years—
Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial
2024 · intervention group · Adults aged 18–70 with obesity and dyslipidemia
700 mg280 mg90 days105
Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study
2024 · SynΩ3 group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP
167 mg83.4 mg4 weeks24
The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial
2017 · Test product (Souvenaid/Fortasyn Connect) · Adults aged 50 years or older with mild probable or possible Alzheimer’s disease
300 mg1.2 g4 weeks16
The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial
2015 · fish-oil capsules · male elite paddlers undertaking an increasing exercise program
3.6 g1.2 g4 weeks11
Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration
2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment
1.05 g200 mg—10
Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study
2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP
180 mg120 mg4 weeks—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye
650 mg350 mg5 years—
The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial
2024 · Group (2) / EP (EPA plus placebo) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women
1 g400 mg12 weeks25
The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial
2024 · Group (3) / CE (curcumin plus EPA) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women
1 g400 mg12 weeks25
Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study
2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed
225 mg800 mg3 years401
Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study
2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed
225 mg800 mg3 years399